You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科濟藥業-B(02171.HK)年度淨虧損約7.98億元
格隆匯 03-18 19:03

格隆匯3月18日丨科濟藥業-B(02171.HK)公告,截至2024年12月31日止年度,集團的收益約爲人民幣39.4百萬元,主要來自賽愷澤(澤沃基奧侖賽注射液,自體BCMA CAR-T細胞產品),乃以出廠價格而非終端市場價進行計算的。公司的收益於完成產品的出廠交付後確認。此外,截至2024年12月31日止年度,公司就賽愷澤從華東醫藥獲得里程碑付款人民幣75百萬元。由於CAR-T生產存在必需的時間週期,從華東醫藥獲得的訂單數量與出廠交付的數量存在差異。

截至2024年12月31日止年度,公司的淨虧損約爲人民幣798百萬元,較截至2023年12月31日止年度的約人民幣748百萬元增加虧損約人民幣50百萬元。該增加主要是由於其他虧損淨額由截至2023年12月31日止年度的人民幣31百萬元增加人民幣229百萬元至截至2024年12月31日止年度的人民幣260百萬元。有關虧損增加部分被(i)研發開支由截至2023年12月31日止年度的人民幣662百萬元減少人民幣196百萬元至截至2024年12月31日止年度的人民幣466百萬元;及(ii)截至2024年12月31日止年度確認毛利人民幣15百萬元(而截至2023年12月31日止年度則爲零)所抵銷。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account